Itsuya Tanabe

Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.

Interleukin-12 (IL-12) and IL-23 are proinflammatory cytokines and therapeutic targets for inflammatory and autoimmune diseases, including inflammatory bowel diseases, psoriasis, rheumatoid arthritis, and multiple sclerosis. We describe the discovery of APY0201, a unique small molecular IL-12/23 production inhibitor, from activated macrophages and monocytes, and demonstrate ameliorated inflammation in an experimental model of colitis. Through a chemical proteomics approach using a highly sensitive direct nanoflow LC-MS/MS system and bait compounds equipped with the FLAG epitope associated regulator of PIKfyve (ArPIKfyve) was detected. Further study identified its associated protein phosphoinositide kinase, FYVE finger-containing (PIKfyve), as the target protein of APY0201, which was characterized as a potent, highly selective, ATP-competitive PIKfyve inhibitor that interrupts the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(3,5)P2. These results elucidate the function of PIKfyve kinase in the IL-12/23 production pathway and in IL-12/23-driven inflammatory disease pathologies to provide a compelling rationale for targeting PIKfyve kinase in inflammatory and autoimmune diseases.

Tu1864 A Novel Orally Active Phosphatidylinositol 3-Phosphate 5-Kinase (Pikfyve) Inhibitor Ameliorates Mouse Colitis by Inhibition of IL-12 and IL-23 Production From Macrophages

A Novel Orally Active Phosphatidylinositol 3-Phosphate 5-Kinase (Pikfyve) Inhibitor Ameliorates Mouse Colitis by Inhibition of IL-12 and IL-23 Production From Macrophages Ayatoshi Andou, Takashi Yamamoto, Eviryanti Agung, Yukie Seki, Hikaru Nishio, Manami Shuto, Misato Noguchi, Yoichiro Shima, Sen Takeshita, Ryohei Yokoyama, Nobuhiko Hayakawa, Masatsugu Noguchi, Shunsuke Kageyama, Hiroyuki Eda, Makoto Shiozaki, Itsuya Tanabe, Ryusuke Nakagawa, Kuniya Sakurai, Shoji Masataka